RxDoctor Payments Data

Katherine Williams, NP

Family · Marietta, GANPI 1134471485

Payments from drug & device makers

$6,523in general payments, 2019–2025

Across 371 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AbbVie$733
  • Novo Nordisk$596
  • Amgen$512
  • Pfizer$393
  • Takeda Pharmaceuticals U.S.A., Inc.$300
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$6,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,523 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$59,137
Medicare patients
327
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$77,246
MounjaroTirzepatide70$74,473
Evenity (2 Syringes)Romosozumab-Aqqg22$52,951
JardianceEmpagliflozin37$52,446
CreonLipase/Protease/Amylase12$27,184
ProliaDenosumab14$24,230
JanuviaSitagliptin Phosphate24$17,842
TrulicityDulaglutide14$16,471
Tresiba Flextouch U-200Insulin Degludec14$15,069
FarxigaDapagliflozin Propanediol11$9,157
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,575
Atorvastatin Calcium128$1,338
Levothyroxine Sodium142$1,174
Rosuvastatin Calcium65$925
Albuterol Sulfate HfaAlbuterol Sulfate31$913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,281$90,94484 claims
Novo NordiskOzempic$596$77,24670 claims
AmgenEvenity (2 Syringes), Prolia$512$77,18136 claims
Boehringer IngelheimJardiance$212$52,44637 claims
AbbVieCreon, Synthroid$733$27,94523 claims
MerckJanuvia$146$17,84224 claims
AstraZenecaFarxiga$100$9,15711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →